vero
cell
american
type
cultur
collect
grown
dulbecco
modifi
eagl
medium
dmem
gibco
cell
test
neg
mycoplasma
mycoalert
detect
kit
lonza
peptid
produc
standard
fmocsolid
phase
method
cholesterol
tocopherol
bislipid
moieti
attach
peptid
describ
discret
polyethylen
glycol
dpeg
obtain
quanta
biodesign
plain
citi
oh
nipah
viru
genbank
passag
isol
cerebrospin
fluid
patient
obtain
dr
k
b
chua
k
lam
univers
malaya
kuala
lumpur
nipah
viru
prepar
infect
cell
describ
inserm
jean
biosafeti
level
laboratori
lyon
franc
receptorbear
cell
express
omega
peptid
mix
cell
coexpress
envelop
glycoprotein
alpha
peptid
cell
fusion
lead
complement
proteinas
k
merck
millipor
peptid
sampl
mm
tri
mm
nacl
preincub
minut
reaction
mixtur
contain
proteinas
k
peptid
proteolyt
digest
quench
specif
time
point
hour
nonreduc
laemmli
sd
sampl
buffer
sampl
boil
minut
centrifug
second
rel
centrifug
forc
load
trisglicin
gel
novex
constant
v
silver
stain
pierc
enzymelink
immunosorb
assay
perform
frozen
sampl
previous
describ
sera
african
green
monkey
agm
test
interferon
type
ifni
bioassay
base
protect
vesicular
stomat
viru
infect
describ
previous
eightweekold
femal
syrian
golden
hamster
mesocricetu
auratu
janvier
le
genestsaintisl
franc
infect
intranas
plaqueform
unit
pfu
niv
dmem
group
anim
treat
daili
peptid
mgkg
day
postinfect
pi
anim
infect
day
pfu
niv
lethal
dose
ld
medium
receiv
vehicl
aguett
water
untreat
group
four
healthi
agm
chlorocebu
aethiop
sabaeu
saint
kitt
coloni
acclim
hous
cynbios
lyon
franc
day
peptid
mgml
administ
intratrach
mgkg
day
use
microspray
microspray
aerosol
penncenturi
subcutan
sc
administr
anim
receiv
mgml
peptid
day
anim
anesthet
use
ketamin
imalgen
merial
lyon
franc
mgkg
intramuscularli
im
midazolam
midazolam
mgml
aguett
lyon
franc
mgkg
im
peptid
administr
xylocain
nd
spray
arytenoid
larynx
anim
avoid
cough
anim
observ
food
consumpt
clinic
sign
mortal
twice
daili
blood
collect
femor
venipunctur
ethylenediaminetetraacet
acid
edta
vacutain
tube
mltube
centrifug
minut
rpm
conserv
twentyfour
hour
peptid
administr
organ
collect
conserv
eleven
healthi
male
agm
saint
kitt
acclim
hous
day
experi
infect
perform
day
pfu
niv
ml
dmem
peptid
treatment
perform
group
use
either
administr
given
intub
anim
day
mgkg
ml
ppi
water
aguett
sc
day
mgkg
ml
ppi
water
aguett
figur
untreat
anim
receiv
vehicl
contain
ml
aguett
water
treatment
perform
anesthesia
one
control
anim
receiv
lipopeptid
treatment
sc
without
infect
anim
observ
daili
day
kept
videocamera
observ
weight
temperatur
measur
anesthesia
blood
sampl
day
pi
hematolog
analyz
use
melet
schloes
within
hour
collect
edtacontain
tube
euthanasia
perform
inject
ml
intracardiac
twice
blood
organ
kept
nipah
viru
neutral
antibodi
assay
describ
previous
cytopath
effect
reveal
crystal
violet
stain
titer
defin
reciproc
valu
last
serum
dilut
complet
inhibit
data
normal
distribut
equal
varianc
test
perform
prism
graphpad
softwar
data
describ
mean
standard
deviat
unless
otherwis
state
bonferroni
posttest
perform
compar
replic
mean
comparison
hamster
surviv
done
mantelcox
analysi
anim
handl
strict
accord
good
anim
practic
defin
french
nation
charter
ethic
anim
experiment
effort
made
minim
suffer
anim
work
approv
region
ethic
committe
evalu
commun
au
centr
l
animaleri
de
transit
de
l
en
au
pbe
et
au
laboratoir
french
ministri
high
educ
research
experi
perform
inserm
jean
laboratori
french
anim
regul
committe
previous
show
peptid
sequenc
correspond
ctermin
heptadrepeat
region
hrc
anoth
paramyxovirida
famili
parainfluenza
type
niv
fusion
entri
effect
peptid
deriv
niv
f
conjug
cholesterol
inhibitori
peptid
enhanc
niv
antivir
activ
target
peptid
plasma
membran
recent
studi
biophys
correl
peptid
antivir
properti
use
hrcderiv
inhibitor
join
lipid
flexibl
peg
linker
solubl
aqueou
organ
media
therefor
plasmaextracellular
fluid
membran
nontox
nonimmunogen
studi
took
advantag
inform
develop
seri
effect
niv
inhibitor
base
highli
effect
viki
sequenc
shown
prophylact
therapeut
efficaci
prototyp
peptid
vivo
explor
effect
modul
conjug
lipid
moieti
flexibl
linker
replac
tradit
peg
flexibl
linker
dpeg
chain
length
modul
stage
peptid
synthesi
comparison
cholesterol
moieti
use
prototyp
peptid
studi
tocopherol
tabl
tocopherol
specif
interact
membran
may
improv
biophys
characterist
lipopeptid
viki
sequenc
peptid
linker
unconjug
ctermin
conjug
singl
doubl
lipid
interest
assess
abil
inhibit
cellcel
fusion
mediat
viral
glycoprotein
figur
cholesterol
tocopherol
conjug
improv
peptid
inhibit
cellcel
fusion
mediat
niv
glycoprotein
compar
unconjug
expect
nm
nm
respect
peptid
superior
bislipid
conjug
peptid
show
conjug
peptid
singl
cholesterol
moieti
decreas
proteas
sensit
figur
supplementari
figur
show
viki
seri
lipid
peptid
incub
presenc
proteinas
k
time
hour
hour
halflif
intact
peptid
fraction
second
minut
minut
minut
minut
respect
unconjug
peptid
undetect
minut
singl
cholesterol
tocopherol
conjug
enhanc
resist
proteas
degrad
compar
either
bischolesterol
bistocopherol
conjug
thu
analyz
vivo
compar
efficaci
niv
hamster
figur
previous
determin
ld
establish
pharmacokinet
biodistribut
hrcderiv
peptid
hamster
mice
studi
determin
appropri
dose
target
upper
lower
respiratori
tract
niv
infect
figur
select
pfu
uniformli
lethal
day
pi
experi
hamster
treat
volum
vehicl
peptid
mgkg
day
infect
figur
peptid
treatment
improv
surviv
approach
day
ie
p
versu
lethal
day
untreat
anim
peptid
given
time
effect
face
high
inoculum
niv
chosen
primat
studi
biodistribut
yield
highest
lung
concentr
littl
system
distribut
along
noninferior
effect
hamster
also
interest
base
find
tocopherol
conjug
enhanc
potenc
paramyxovirus
rais
possibl
broadspectrum
protect
peptid
data
shown
assess
halflif
distribut
peptid
either
alon
mgkg
plu
sc
mgkg
agm
primat
studi
administr
vs
hamster
use
deliv
peptid
respiratori
tract
limit
passag
gut
use
combin
sc
rout
comparison
alon
previou
studi
show
sc
administr
yield
high
serum
brain
concentr
hamster
mice
aim
prophylaxi
via
peptid
retent
upper
lower
respiratori
tract
treatment
well
toler
signific
advers
effect
relat
administr
peptid
concentr
measur
serum
brain
lung
tissu
anim
administr
rout
figur
combin
sc
administr
free
peptid
detect
serum
hour
peak
nm
drop
nm
hour
accompani
peptid
detect
hour
brain
nm
lung
nm
contrast
administr
alon
serum
peptid
peak
nm
shortli
administr
hour
undetect
hour
peptid
administ
respiratori
rout
thu
concentr
effect
lung
achiev
nm
hour
determin
whether
peptid
administr
affect
level
ifni
serum
treat
anim
might
nonspecif
favor
protect
sensit
ifni
bioassay
perform
sera
taken
hour
hour
hour
posttreat
show
increas
ifni
test
anim
data
shown
next
assess
efficaci
niv
infect
agm
accord
schedul
figur
experi
figur
agm
receiv
pfu
viru
serumfre
dmem
mock
base
heterogen
dose
niv
use
infect
agm
previou
work
protect
high
infecti
dose
viru
hamster
set
high
bar
antivir
prophylaxi
anim
studi
perform
other
primat
experi
agm
succumb
much
lower
dose
niv
suggest
dose
use
exce
lethal
log
peptid
given
day
daili
day
pi
either
sc
treatment
continu
day
use
mgkg
peptid
mgkg
sc
figur
group
anim
receiv
treatment
alon
schedul
untreat
anim
succumb
infect
day
figur
tabl
treatment
result
surviv
protocol
end
protocol
day
anim
surviv
treat
group
treat
anim
succumb
end
protocol
expector
peptid
administr
tabl
underlin
import
optim
peptid
deliveri
respiratori
area
activ
investig
peptid
show
protect
lethal
outcom
infect
face
excess
lethal
inoculum
niv
treat
anim
surviv
infect
anim
surviv
infect
administr
peptid
figur
free
peptid
detect
serum
low
level
peak
nm
day
infect
figur
anim
also
high
titer
antiniv
neutral
antibodi
figur
wherea
treat
agm
figur
succumb
earli
protocol
day
undetect
level
serum
neutral
antibodi
surviv
anim
figur
receiv
combin
plu
sc
administr
free
peptid
present
serum
high
level
day
onward
level
nm
treatment
end
day
anim
like
survivor
exhibit
high
titer
antiniv
neutral
antibodi
two
untreat
anim
surviv
day
exhibit
detect
neutral
antibodi
respons
although
lower
surviv
treat
anim
suggest
treatment
slow
cours
infect
allow
surviv
anim
develop
protect
antivir
humor
respons
set
clinic
observ
collect
tabl
supplementari
figur
supplementari
tabl
infect
anim
show
trace
infect
lung
hemorrhag
brain
die
biochem
cellular
analysi
blood
includ
lymphopenia
day
associ
later
monocytosi
figur
consist
previou
studi
niv
model
infect
anim
tend
toward
neutrophilia
thrombocytopenia
week
supplementari
tabl
supplementari
figur
without
signific
variat
supplementari
figur
among
manifest
ill
recoveri
declin
health
anim
later
succumb
preced
fall
food
consumpt
supplementari
figur
anorexia
squirrel
monkey
niv
infect
agm
wherea
consumpt
survivor
fell
recov
end
protocol
surviv
anim
consum
food
similarli
uninfect
anim
clinic
sign
ill
full
recoveri
broad
applic
fusioninhibitori
antivir
strategi
base
fact
major
fusion
protein
mediat
envelop
viral
entri
molecular
region
interact
mediat
viruscel
fusion
identifi
primari
sequenc
lipopeptid
fusion
inhibitor
may
design
basi
pathogen
genet
inform
strategi
deliv
antivir
via
respiratori
rout
target
membran
site
action
broadli
appli
approach
human
niv
outbreak
field
set
case
larg
outbreak
need
recombin
monoclon
antibodi
gener
passiv
immunoprophylaxi
hev
niv
challeng
target
rural
popul
wider
swath
expos
peopl
event
global
spread
face
potenti
rapid
evolut
paramyxovirus
antibodyescap
mutat
antivir
rapidli
adjust
address
resist
variant
strain
solut
need
deliv
target
popul
rural
area
even
popul
expand
vastli
via
human
transmiss
inhal
administr
peptid
describ
would
provid
solut
previou
work
identifi
specif
biophys
featur
lipopeptid
import
paramyxoviru
antivir
efficaci
foundat
peptid
sequenc
deriv
hrc
domain
human
parainfluenza
viru
inhibit
niv
studi
modifi
prototyp
peptid
exhibit
prophylact
therapeut
efficaci
vivo
focus
role
lipid
moieti
tether
peptid
inhibitor
target
membran
cellbas
experi
show
peptid
effect
niv
fusion
inhibitor
figur
stabl
proteas
degrad
figur
lipopeptid
show
efficaci
intranas
prophylaxi
infect
hamster
high
inoculum
niv
data
shown
reach
high
level
lung
therefor
could
protect
effect
concentr
blood
reach
cn
featur
would
ideal
prophylaxi
uninfect
person
niv
pathogen
escal
via
direct
battohuman
humantohuman
spread
primat
efficaci
studi
infect
inoculum
viru
later
shown
ld
despit
overwhelm
inoculum
viru
one
third
anim
surviv
infect
return
health
survivor
exhibit
high
titer
antiniv
neutral
antibodi
administr
surrog
inhal
administr
develop
system
nebul
aerosol
peptid
inhal
deliveri
administr
could
futur
translat
use
human
develop
fusion
inhibitor
would
set
stage
platform
technolog
suitabl
paramyxovirus
respiratori
syncyti
viru
parainfluenza
also
envelop
virus
similar
entri
pathway
sequenc
peptid
region
particip
fusion
intermedi
suffici
inform
gener
fusion
inhibitor
knowledg
alreadi
avail
virus
infer
genet
inform
pathogen
case
viral
evolut
emerg
new
strain
rapid
develop
new
antivir
base
modifi
peptid
sequenc
would
feasibl
effort
increas
inhibitor
potenc
enhanc
interact
peptid
correspond
hrc
domain
expect
creat
barrier
resist
tocopherol
conjug
proven
provid
adequ
human
safeti
pharmacokinet
strategi
would
like
extend
tocopherolconjug
peptid
peptid
compon
metabol
compon
amino
acid
peptid
gener
regard
safe
efficaci
via
inhal
rout
administr
mean
antivir
practic
feasibl
within
reach
use
field
outbreak
occur
